| Drug Name |
Trospium |
| Drug ID |
BADD_D02305 |
| Description |
Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably.[L6208] An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination.[L6208] Trospium is manufactured by _Indevus Pharmaceutical Inc._ and was granted FDA approval in 2007.[L6211] |
| Indications and Usage |
For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency, detrusor instability and frequency of micturition. |
| Marketing Status |
approved |
| ATC Code |
G04BD09 |
| DrugBank ID |
DB00209
|
| KEGG ID |
D01103
|
| MeSH ID |
C003330
|
| PubChem ID |
5284632
|
| TTD Drug ID |
D05TIB
|
| NDC Product Code |
Not Available |
| UNII |
T4Y8ORK057
|
| Synonyms |
trospium chloride | azoniaspiro compound XVII | azoniaspiro(3 alpha-benziloyloxynortropane-8,1'- pyrrolidine) chloride | Spasmex | Uraton | Spasmolyt | Spasmo-Urgenin TC | Spasmo-lyt | Spasmo-Rhoival TC | Trospi | Ceris | Uraplex | Spasmo-Urgenin |
